Bortezomib, doxorubicin and dexamethasone association is an effective option for plasma cell leukemia induction therapy
- 1 January 2008
- journal article
- letter
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 49 (10), 2012-2014
- https://doi.org/10.1080/10428190802290660
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: Do specific cytogenetic and immunophenotypic characteristics influence treatment outcome?Leukemia Research, 2008
- Genetic aberrations and survival in plasma cell leukemiaLeukemia, 2008
- Stem-Cell Transplantation for Multiple Myeloma in the Era of Novel DrugsJournal of Clinical Oncology, 2008
- Significantly Better Prognosis for Patients with Primary Plasma Cell Leukemia than for Patients with Secondary Plasma Cell LeukemiaActa Haematologica, 2007
- Efficacy and safety of bortezomib in patients with plasma cell leukemiaCancer, 2007
- Combination Chemotherapy with Bortezomib, Cyclophosphamide and Dexamethasone may be Effective for Plasma Cell LeukemiaJapanese Journal of Clinical Oncology, 2007
- Managing plasma cell leukemiaLeukemia & Lymphoma, 2007
- International uniform response criteria for multiple myelomaLeukemia, 2006
- Bortezomib is effective in primary plasma cell leukemiaLeukemia & Lymphoma, 2006
- Primary plasma cell leukaemia: a report of 18 casesLeukemia Research, 2001